Arno Therapeutics Inc. (ARNI)

Overview

Arno Therapeutics, Inc. is a biopharmaceutical enterprise committed to the development of novel treatments addressing cancer and other life-threatening illnesses. Founded in 2005 and headquartered in Flemington, New Jersey, the company focuses on leveraging its expertise in drug development to bring innovative therapies to market. With a strategic approach to partnerships, Arno Therapeutics has entered into various license and co-development agreements, including with Invivis Pharmaceuticals, Inc.; the Regents of the University of Minnesota; the Ohio State University Innovation Foundation, and Leica Biosystems Newcastle Ltd. These collaborations aim to enhance its product development pipeline and accelerate the delivery of its therapeutic solutions to patients in need.

Products and Services

• Onapristone

This product is in the forefront of Arno Therapeutic's innovative pipeline, representing a type 1 anti-progestin hormone blocker. Currently undergoing Phase I/II clinical studies, Onapristone is being developed for the treatment of various solid tumors including breast, endometrial, and others specifically targeting post-menopausal women. Additionally, it is being analyzed for its efficacy in men with advanced castration-resistant prostate cancer. Onapristone aims to offer a new therapeutic option for patients with these challenging conditions.

• AR-12

AR-12 stands as an orally administered candidate tailored to combat solid tumors and hematological malignancies. Having completed Phase I clinical trials, this potential cancer treatment is distinguished for its versatility, undergoing further pre-clinical studies to explore its efficacy against various anti-microbial targets. The development of AR-12 underscores Arno Therapeutics' commitment to diversifying its oncology portfolio and addressing unmet medical needs in cancer treatment.

• AR-42

A novel therapeutic offering, AR-42 encapsulates the company’s stride towards innovation in orally available cancer therapies. Currently, it is in Phase I of investigator-initiated clinical studies targeting both hematological malignancies and solid tumors. The inception of AR-42 reflects Arno Therapeutics’ ongoing pursuit to pioneer novel and effective treatment alternatives for patients grappling with various cancer forms.